TRIP13 inhibition may be useful in treating diverse cancer types, including hepatocellular carcinoma (HCC) [5–7], myeloma [8], colon cancer [9–12], chronic lymphocytic leukemia (CLL) [13], bladder cancer [14,15], head and neck squamous cell carcinoma (HNSCC) [16], non-small cell lung cancer (NSCLC) [17], and prostate cancer [18]. This evidence concerns the gene TRIP13 and non-small cell lung carcinoma.